Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Vanguard Total International Stock Index Fund ETF (VXUS) Price & Performance

Halozyme Therapeutics Inc. Common StockTrade
Vanguard Total International Stock Index Fund ETFTrade

Price performance (Past 24H)

Key statistics

Halozyme Therapeutics Inc. Common Stock vs Vanguard Total International Stock Index Fund ETF — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $109.67 (market cap $12.58B), while Vanguard Total International Stock Index Fund ETF trades at $84.51 (market cap $665.70B). The key difference: Vanguard Total International Stock Index Fund ETF is far larger — about 52.9× Halozyme Therapeutics Inc. Common Stock's market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, Vanguard Total International Stock Index Fund ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 0 Days and Vanguard Total International Stock Index Fund ETF for 55 Days on average.

HALOVXUS
Market Cap
$12.58B$665.70B
Volume
2,179,2784,890,695
Sector
HealthSector/Thematic
52-Week High
$115.22$88.41
52-Week Low
$61.63$72.17
Typical Hold Time
0 Days55 Days
Enterprise Value
$14.49B—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Halozyme Therapeutics Inc. Common Stock

No Aura AI signal available yet.

Vanguard Total International Stock Index Fund ETF

VXUS, the Vanguard Total International Stock ETF, is trading at $84.78, down 1.19% on the day, with a bearish technical signal driven by moving averages. The ETF provides diversified exposure to international developed and emerging markets outside the U.S. Recent news highlights its role in portfolio diversification and long-term growth potential, with several financial firms increasing their positions in Q2 2026.

The outlook for VXUS hinges on international market performance relative to the U.S., offering a hedge against domestic downturns. Key risks include currency fluctuations, geopolitical tensions, and the ETF's inability to reclaim foreign tax credits in IRAs. Its low-cost, broad diversification presents a strategic opportunity for long-term investors seeking global equity exposure.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

HALO
100% Buy0% Sell
Avg holding period · 0 Days
VXUS
81% Buy19% Sell
Avg holding period · 55 Days

About Halozyme Therapeutics Inc. Common Stock

Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.

Read more on HALO →

About Vanguard Total International Stock Index Fund ETF

VXUS is a comprehensive, low-cost ETF that tracks the FTSE Global All Cap ex US Index, providing exposure to over 8,500 stocks in both developed and emerging markets outside the United States. It serves as a foundational building block for international diversification, allowing investors to own a market-cap-weighted slice of the entire non-U.S. investable equity universe in a single vehicle.

Read more on VXUS →